Global Cough Hypersensitivity Syndrome Market Size study, By Drug Class (Inhales Corticosteroids, Antitussive Agents, Short-acting Beta-2 Agonists, Anticholinergics, Proton Pump Inhibitors, Antihistamines, Others), Route of Administration (Oral, Inhalatio

Global Cough Hypersensitivity Syndrome Market Size study, By Drug Class (Inhales Corticosteroids, Antitussive Agents, Short-acting Beta-2 Agonists, Anticholinergics, Proton Pump Inhibitors, Antihistamines, Others), Route of Administration (Oral, Inhalation, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Regional Forecasts 2022-2028

Global Cough Hypersensitivity Syndrome Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Cough hypersensitivity syndrome (CHS) is a clinical syndrome which causes troublesome coughing. Cough hypersensitivity syndrome triggers due to asthma, postnasal drip, reflux disease, and allergic factors among others. Increasing incidences of chronic respiratory diseases and growing healthcare sector in emerging economies as well as rising trend towards sedentary lifestyle are key drivers for growth of Cough Hypersensitivity Syndrome Market. For instance, according to World Health Organization (WHO)- Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death globally. During 2019, globally 3.23 million people succumbs to COPD. Furthermore, as per The Office of Disease Prevention and Health Promotion (ODPHP) – As of 2020, in USA around 25 million people have asthma and around 14.8 million adults have been diagnosed with COPD. Moreover, annual health care expenditures for asthma disease were estimated at USD 20.7 billion. Also, surging geriatric population and increasing number of clinical trials are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high treatment cost of Cough Hypersensitivity Syndrome impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Cough Hypersensitivity Syndrome Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing prevalence of respiratory disorders and surging healthcare expenditure as well as presence of leading market players in the region. Whereas, North America is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as rising geriatric population and increasing investment towards healthcare infrastructure development in the region, would create lucrative growth prospects for the Cough Hypersensitivity Syndrome Market across the Asia Pacific region.

Major market players included in this report are:
Akorn, Incorporated (US)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
Boehringer Ingelheim International GmbH. (Germany)
AstraZeneca (U.K.)
Johnson & Johnson Private Limited (U.S.)


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class

Inhales Corticosteroids
Antitussive Agents
Short-acting Beta-2 Agonists
Anticholinergics
Proton Pump Inhibitors
Antihistamines
Others
By Route of Administration
Oral
Inhalation
Others
By End-Users
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Cough Hypersensitivity Syndrome Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors



Companies Mentioned

Akorn, Incorporated (US)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
Boehringer Ingelheim International GmbH. (Germany)
AstraZeneca (U.K.)
Johnson & Johnson Private Limited (U.S.)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.